Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


MaxDiscovery™ Apolipoprotein B (ApoB) ELISA Kit

Product Description
The MaxDiscovery™ Apolipoprotein B (ApoB) ELISA Kit is an enzyme immunoassay that analyzes the quantity of ApoB in cells, tissues, serum, plasma or cultured cells. Apoliporotein B is the primary apoliporotein of low-density lipoproteins (LDL), which is responsible for carrying cholesterol to tissues. Apoliporotein B acts as a ligand for LDL receptors in various cells throughout the body. The protein has two main isoforms, ApoB-48 and ApoB-100. In humans ApoB-48 is synthesized in the small intestine while ApoB-100 is made in the liver. There is significant evidence that shows that high levels of Apolipoprotein B can lead to plaques that cause atherosclerotic coronary disease. In fact, Apolipoprotein B levels are thought to be an even better indicator of heart disease risk than total cholesterol or LDL. Bioo Scientific’s ApoB ELISA kit is an immunoassay that can be used to measure ApoB levels in cells, serum and tissue with minimal sample preparation. The standard curve spans the range of 0-200 ng/mL. Like most ELISA assays, the MaxDiscovery™ ApoB ELISA Test relies on a Horseradish Perioxidase (HRP) conjugated antibody and the TMB (3,3´,5,5´-tetramethylbenzidine) substrate. TMB is a chromogen that yields a blue color when oxidized with hydrogen peroxide (catalyzed by HRP) that has major absorbances at 370 nm and 652 nm. The color then changes to yellow with the addition of acid with maximum absorbance at 450 nm. The relative amount of ApoB protein in the cells will be directly proportional to the amount of signal that is obtained at 450 nm.
Product MaxDiscovery™ Apolipoprotein B (ApoB) ELISA Kit
Company BIOO Scientific - Product Directory
Price Request a quote
More Information View company product page
Catalog Number 1 x 384 wells
Quantity Unspecified
Company Logo

BIOO Scientific - Product Directory
3913 Todd Lane Suite 312 Austin, TX 78744, USA

Tel: +1 512-707-8993
Fax: +1 512-707-8122
Email: info@biooscientific.com



Scientific News
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!